HC Wainwright Estimates Indivior’s Q2 Earnings (NASDAQ:INDV)

Indivior PLC (NASDAQ:INDV) – Equities researchers at HC Wainwright issued their Q2 2026 EPS estimates for shares of Indivior in a research note issued on Monday, January 12th. HC Wainwright analyst B. Folkes forecasts that the company will earn $0.74 per share for the quarter. HC Wainwright has a “Buy” rating and a $48.00 price target on the stock. The consensus estimate for Indivior’s current full-year earnings is $1.22 per share. HC Wainwright also issued estimates for Indivior’s Q3 2026 earnings at $0.75 EPS, Q4 2026 earnings at $0.79 EPS and FY2030 earnings at $3.77 EPS.

A number of other brokerages have also issued reports on INDV. Northland Securities set a $40.00 price target on Indivior in a research note on Friday, October 31st. Craig Hallum reaffirmed a “buy” rating and set a $41.00 target price on shares of Indivior in a report on Friday, October 31st. Zacks Research upgraded shares of Indivior from a “hold” rating to a “strong-buy” rating in a research report on Monday, November 3rd. Weiss Ratings restated a “hold (c)” rating on shares of Indivior in a research report on Friday, October 31st. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $36.00 price objective on shares of Indivior in a research note on Wednesday, December 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $34.57.

Indivior Price Performance

NASDAQ INDV opened at $34.56 on Tuesday. Indivior has a 12 month low of $7.62 and a 12 month high of $38.00. The firm has a market capitalization of $4.32 billion, a PE ratio of 37.57 and a beta of 0.75. The company’s 50 day simple moving average is $34.22 and its 200 day simple moving average is $26.19.

Indivior (NASDAQ:INDV) last released its quarterly earnings results on Thursday, October 30th. The company reported $0.72 EPS for the quarter, topping analysts’ consensus estimates of $0.38 by $0.34. The company had revenue of $314.00 million for the quarter, compared to the consensus estimate of $257.66 million. Indivior had a net margin of 9.83% and a negative return on equity of 90.79%.

Insider Transactions at Indivior

In related news, Director Barbara Ryan acquired 775 shares of the business’s stock in a transaction on Monday, January 5th. The shares were purchased at an average price of $35.39 per share, for a total transaction of $27,427.25. Following the acquisition, the director owned 1,963 shares in the company, valued at approximately $69,470.57. This represents a 65.24% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Daniel A. Ninivaggi acquired 775 shares of Indivior stock in a transaction on Monday, January 5th. The shares were purchased at an average cost of $35.39 per share, with a total value of $27,427.25. Following the completion of the purchase, the director directly owned 16,923 shares of the company’s stock, valued at approximately $598,904.97. This represents a 4.80% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have bought a total of 4,871 shares of company stock worth $172,385 in the last three months.

Hedge Funds Weigh In On Indivior

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Oaktree Capital Management LP raised its stake in Indivior by 2,241.6% during the 3rd quarter. Oaktree Capital Management LP now owns 257,785,398 shares of the company’s stock valued at $6,215,206,000 after purchasing an additional 246,776,273 shares during the period. Two Seas Capital LP raised its position in Indivior by 0.4% during the second quarter. Two Seas Capital LP now owns 11,407,795 shares of the company’s stock valued at $168,151,000 after buying an additional 41,018 shares during the period. Goldman Sachs Group Inc. lifted its stake in Indivior by 18.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 8,368,996 shares of the company’s stock worth $79,757,000 after acquiring an additional 1,299,425 shares in the last quarter. Rubric Capital Management LP lifted its stake in Indivior by 31.6% in the 2nd quarter. Rubric Capital Management LP now owns 4,647,179 shares of the company’s stock worth $68,499,000 after acquiring an additional 1,117,140 shares in the last quarter. Finally, Newtyn Management LLC grew its stake in Indivior by 61.1% during the 3rd quarter. Newtyn Management LLC now owns 4,200,000 shares of the company’s stock valued at $101,262,000 after acquiring an additional 1,592,982 shares in the last quarter. 60.33% of the stock is currently owned by hedge funds and other institutional investors.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.